Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $97.50 short put and a strike $92.50 long put offers a potential 9.89% return on risk over the next 37 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $97.50 by expiration. The full premium credit of $0.45 would be kept by the premium seller. The risk of $4.55 would be incurred if the stock dropped below the $92.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Mylan Launches First Adcirca Generic, Stock Moves Up
Mon, 13 Aug 2018 20:45:22 +0000
Today, Mylan Pharmaceuticals (MYL) announced the launch of tadalafil tablets USP (20 mg) in the United States. The drug is the first generic version of Eli Lilly’s (LLY) Adcirca (tadalafil) approved by the FDA.
Novo Nordisk’s Long-Acting Insulins: A Performance Overview
Mon, 13 Aug 2018 18:55:02 +0000
Tresiba, Novo Nordisk’s (NVO) long-acting insulin, generated revenues of 3.7 billion Danish kroner in the first half of 2018, reflecting an ~11% YoY (year-over-year) growth in local currencies.
Can Victoza Continue to Boost Novo Nordisk’s Revenue Growth?
Mon, 13 Aug 2018 17:25:02 +0000
Novo Nordisk’s (NVO) Victoza generated revenues of 11.7 billion Danish kroner in the first half of 2018 compared to 11.5 billion Danish kroner in the first half of 2017, a ~2% YoY (year-over-year) growth and a ~12% YoY growth in local currencies.
Novo Nordisk: A Financial Overview after the First Half of 2018
Mon, 13 Aug 2018 15:50:28 +0000
Novo Nordisk (NVO) reported net revenues of 54.3 billion Danish kroner in the first half of 2018 compared to 57.1 billion Danish kroner in H1 2017. That’s a ~5% YoY (year-over-year) decline.
Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings
Mon, 13 Aug 2018 13:48:01 +0000
Eli Lilly's (LLY) stock is up 15% since announcement of earnings in July. Let us have a look at the reasons for the same.
Also on Market Tamer…
Follow Us on Facebook